You can buy or sell XENE and other stocks, options, ETFs, and crypto commission-free!
Xenon Pharmaceuticals, Inc. engages in discovering and developing therapeutics to improve the lives of patients with neurological disorders. It focuses on the treatment of epilepsy. Read More Its products include XEN496, XEN1101, XEN901, and XEN007. The company was founded by Simon Neil Pimstone, Johannes J. P. Kastelein, and Michael R. Hayden on November 5, 1996 and is headquartered in Burnaby, Canada.
Burnaby, British Columbia
52 Week High
52 Week Low
Stock Price, News, & Analysis for Xenon Pharmaceuticals
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. The company uses Extreme Genetics, a core enabling discovery platform for the discovery of validated drug targets by studying rare human diseases with extreme traits, including diseases caused by mutations in ion channels, known as channelopathies. It clinical development pipeline includes XEN1101, a Kv7 potassium channel opener for the treatment...
Seeking AlphaMar 6
Xenon Pharmaceuticals (XENE) CEO Simon Pimstone on Q4 2018 Results - Earnings Call Transcript
Xenon Pharmaceuticals (NASDAQ:XENE) Q4 2018 Results Earnings Conference Call March 6, 2019 4:30 PM ET Company Participants Jodi Regts - VP, Corporate Affairs and IR Simon Pimstone - CEO Ian Mortimer - President and CFO Conference Call Participants Stephen Willey - Stifel Maurice Raycroft - Jefferies Operator Good day, ladies and gentlemen, and welcome to the Fourth Quarter 2018 Xenon Pharmaceuticals Incorporated Financial Results Conference Call. [Operator Instructions] As a reminder, this conferen...
Guru FocusMar 6
Xenon Pharmaceuticals Reports 2018 Financial Results and Provides Corporate Update
Multiple Neurology-Focused Products Anticipated to be in Phase 2 or Later Stage Development in 2019 Global XEN1101 Phase 2b Clinical Trial Underway with Data Anticipated in Second Half of 2020 Conference Call at 4:30 pm ET Today BURNABY, British Columbia, March 06, 2019 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a clinical stage biopharmaceutical company, today reported its financial results for the year ended December 31, 2018 and provided a corporate update. Dr. Simon Pimstone, Xe...
Expected May 7, After Hours